Theraclion, a Paris, France firm, won European CE Mark approval for its EchoPulse focused ultrasound system to treat breast fibroadenomas, common benign tumors. EchoPulse uses ultrasound to both visualize and attack tumors in real time, and as an outpatient procedure it doesn’t require general anesthesia.
The company hopes to expand the use of its technology to other types of tumors in the future.
From the announcement:
“I used the EchoPulse to treat 11 patients during a clinical trial at the American Hospital of Paris from January to October 2012. The results from this technique are encouraging with a 60% volume reduction of fibroadenoma in an average period of 6 months. EchoPulse could represent an interesting alternative to classical surgery” adds Dr Marc Abehsera from the medical imaging service at the American Hospital of Paris.
A clinical trial on 40 patients has shown the efficiency and the excellent tolerance of echotherapy for this type of pathology. To this day, 48 fibroadenomas have been treated in 3 French centers (Lille Jeanne de Flandres Hospital, the Valenciennes Hospital and the American Hospital of Paris) and one center in Bulgaria (the University Hospital of Sofia), with significant volume reductions accompanied by the resolution of symptoms.
Product page: EchoPulse…
Press release: Theraclion receives CE marking approval for its ultrasonic device EchoPulse, in the non-invasive treatment of breast fibroadenomas
Your information will never be shared with any third party.